CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Shire Human Genetic Therapies against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 7, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 21, 2018
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 20, 2018
Antibodies With Modified Affinity To Fcrn That Promote Antigen ClearanceCHUGAI SEIYAKU KABUSHIKI KAISHAFeb 5, 2018

Explore Shire Human Genetic Therapies's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 7, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jun 5, 2024Pulmonary Delivery Of Mrna To Non-Lung Target Cells1
Aug 4, 2021Methods And Compositions For Cns Delivery Of Iduronate-2-Sulfatase1
May 19, 2021Methods And Compositions For Delivering Mrna Coded Antibodies4
Dec 9, 2020Cns Delivery Of Therapeutic Agents1
Aug 7, 2019Methods For Purification Of Messenger Rna2
Nov 14, 2018Mrna Therapy For Argininosuccinate Synthetase Deficiency1
Oct 24, 2018Mrna Therapy For The Treatment Of Ocular Diseases1
Sep 12, 2018Purification Of Iduronate-2-Sulfatase1
Feb 14, 2018Delivery Of Mrna For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases2

Top competitors of Shire Human Genetic Therapies

List of top competitors of Shire Human Genetic Therapies based on patent oppositions.